Laurie Letvak

5.2k citations

31 papers · 981 indexed · h-index 14

Hematology top 1%
Genetics top 2%
Rheumatology top 2%
Oncology
Public Health, Environmental and Occupational Health

Co-authors: Jörge E. Cortes Hagop M. Kantarjian Mary Beth Rios Stefan Faderl Francis J. Giles Guillermo Garcia‐Manero Moshe Talpaz Alessandra Ferrajoli
Topics: Chronic Myeloid Leukemia Treatments (24 papers)Chronic Lymphocytic Leukemia Research (17 papers)Acute Lymphoblastic Leukemia research (13 papers)
Cited by: Hematology Genetics Rheumatology
Journals: Journal of Clinical Oncology Blood Cancer
Partner nations: United States Switzerland Germany

In The Last Decade

Laurie Letvak

31 papers receiving 960 citations

Peers

Countries citing papers authored by Laurie Letvak

Since Specialization

Citations

This map shows the geographic impact of Laurie Letvak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurie Letvak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurie Letvak more than expected).

Fields of papers citing papers by Laurie Letvak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurie Letvak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurie Letvak. The network helps show where Laurie Letvak may publish in the future.

Co-authorship network of co-authors of Laurie Letvak

This figure shows the co-authorship network connecting the top 25 collaborators of Laurie Letvak. A scholar is included among the top collaborators of Laurie Letvak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laurie Letvak. Laurie Letvak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Outcome after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen for Adults with De Novo or Minimally Treated Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) 2008 ·Blood ·Deborah A. Thomas,Hagop M. Kantarjian,Jörge E. Cortes,Farhad Ravandi,Stefan Faderl,Dan Jones,Laurie Letvak,Partow Kebriaei,Richard E. Champlin,Susan O’Brien	17
2	Efficacy of nilotinib (AMN107) in patients (Pts) with newly diagnosed, previously untreated philadelphia chromosome (Ph)- positive chronic myelogenous leukemia in early chronic phase (CML-CP) 2008 ·Journal of Clinical Oncology ·Jörge E. Cortes,Susan O’Brien,(unknown),G. Borthakur,Jacobus W. A. Burger,(unknown),G. García-Manero,Laurie Letvak,Hagop M. Kantarjian	28
3	Results of a multicenter phase II trial for older patients with c‐Kit‐positive acute myeloid leukemia (AML) and high‐risk myelodysplastic syndrome (HR‐MDS) using low‐dose Ara‐C and Imatinib 2007 ·Cancer ·Florian H. Heidel,Jörge E. Cortes,Frank G. Rücker,Walter E. Aulitzky,Laurie Letvak,Thomas Kindler,Christoph Huber,Hartmut Döhner,Hagop M. Kantarjian,Thomas Fischer	36
4	Long-Term Follow-Up after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen in Adults with Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL). 2007 ·Blood ·Deborah A. Thomas,Hagop M. Kantarjian,Farhad Ravandi,Stefan Faderl,Guillermo Garcia‐Manero,William G. Wierda,Alessandra Ferrajoli,Srđan Verstovšek,Dan Jones,Laurie Letvak,Richard E. Champlin,Jörge E. Cortes,Susan O’Brien	8
5	Efficacy of Nilotinib (AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). 2007 ·Blood ·Jörge E. Cortes,Susan O’Brien,Elias Jabbour,(unknown),Gautam Borthakur,Jan A. Burger,William G. Wierda,Guillermo Garcia‐Manero,Michelle Thomas,Laurie Letvak,Hagop M. Kantarjian	46
6	Single center phase II trial analysing the role of imatinib/hydroxyurea in patients (pts) with pretreated non-progressive glioblastoma (GBM) as maintenance treatment 2007 ·Journal of Clinical Oncology ·G. Dresemann,Christian Hosius,Zariana Nikolova,Laurie Letvak	2
7	Multimethod Clinical Assessment of Patterns and Prevalence of Nonadherence (NA) to Imatinib Treatment (IMRx) in Patients (Pts) with Chronic Myeloid Leukemia (CML): Results from the ADAGIO Study. 2007 ·Blood ·(unknown),(unknown),(unknown),(unknown),Karen MacDonald,Stefaan Vancayzeele,Sabina De Geest,Laurie Letvak,Tara Albrecht,Ivo Abraham	3
8	Preliminary activity of AMN107, a novel potent oral selective Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP) 2006 ·Journal of Clinical Oncology ·Elias Jabbour,F. Giles,Jörge E. Cortes,(unknown),Farhad Ravandi,G. Borthakur,(unknown),Laurie Letvak,August J. Salvado,Hagop M. Kantarjian	8
9	Therapeutic Drug Monitoring of Imatinib and Impact on Clinical Decision Making. 2006 ·Blood ·(unknown),Yanfeng Wang,Theodore Lagattuta,Brian Druker,Laurie Letvak,Merrill J. Egorin	3
10	Results of a Multicenter Phase II Trial for Older Patients with c-Kit Positive Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Using Low-Dose Ara-C (LDAC) and Imatinib. 2005 ·Blood ·Florian H. Heidel,Jörge E. Cortes,(unknown),Martin Kaufmann,Walter E. Aulitzky,Laurie Letvak,Thomas Kindler,Christoph Huber,Hartmut Döhner,Hagop M. Kantarjian,Thorsten Fischer	2
11	Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL). 2005 ·Blood ·Deborah A. Thomas,Stefan Faderl,Jörge E. Cortes,Susan O’Brien,Francis J. Giles,Guillermo Garcia‐Manero,(unknown),Michael Andreeff,Miloslav Beran,Srđan Verstovšek,Sherry Pierce,Laurie Letvak,August J. Salvado,Richard Champlin,Hagop M. Kantarjian	3
12	Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high‐risk myelodysplastic syndrome, and myeloproliferative disorders 2003 ·Cancer ·Jörge E. Cortes,Francis J. Giles,Susan O’Brien,Deborah A. Thomas,Maher Albitar,Mary Beth Rios,Moshe Talpaz,Guillermo Garcia‐Manero,Stefan Faderl,Laurie Letvak,August J. Salvado,Hagop M. Kantarjian	83
13	Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome 2003 ·Blood ·Jörge E. Cortes,Patricia Ault,Charles Koller,Deborah Thomas,Alessandra Ferrajoli,William G. Wierda,Mary Beth Rios,Laurie Letvak,(unknown),Hagop M. Kantarjian	115
14	High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia 2003 ·Blood ·Hagop M. Kantarjian,Moshe Talpaz,Susan O’Brien,Guillermo Garcia‐Manero,Srđan Verstovšek,Francis J. Giles,Mary Beth Rios,Jianqin Shan,Laurie Letvak,Deborah A. Thomas,Stefan Faderl,Alessandra Ferrajoli,Jörge E. Cortes	298
15	Phase II Study of Paclitaxel and Valspodar (PSC 833) in Refractory Ovarian Carcinoma: A Gynecologic Oncology Group Study 2001 ·Journal of Clinical Oncology ·Paula M. Fracasso,Mark F. Brady,David H. Moore,Joan L. Walker,Peter G. Rose,Laurie Letvak,Thomas M. Grogan,William P. McGuire	75
16	PSC833: initial clinical results in refractory ovarian cancer patients. 1998 ·PubMed ·Abbie L. Fields,Howard S. Höchster,Carolyn D. Runowicz,James L. Speyer,Gary L. Goldberg,(unknown),Peter R. Dottino,Scott Wadler,(unknown),(unknown),J. Mandeli,(unknown),Laurie Letvak	16
17	Safety and Efficacy of I‐Leucovorin Rescue Following High‐Dose Methotrexate for Osteosarcoma 1995 ·Medical and Pediatric Oncology ·Allen M. Goorin,Douglas Strother,David G. Poplack,Laurie Letvak,Martine George,Michael P. Link	12
18	Phase I trial of a 5-day infusion ofL-leucovorin plus daily bolus 5-fluorouracil in patients with advanced gastrointestinal malignancies 1993 ·Cancer Chemotherapy and Pharmacology ·Frank H. Valone,David R. Gandara,Judith Luce,(unknown),Edith A. Perez,(unknown),Martine George,Laurie Letvak	4
19	14-Day Continuous Infusion of Mitoxantrone in Hormone-Refractory Metastatic Adenocarcinoma of the Prostate 1993 ·American Journal of Clinical Oncology ·Philip W. Kantoff,Caroline Block,Laurie Letvak,(unknown)	19
20	Substitution of l-leucovorin for d,l-leucovorin in the rescue from high-dose methotrexate treatment in patients with osteosarcoma 1993 ·Anti-Cancer Drugs ·(unknown),(unknown),Resa Robertson,Martine George,Laurie Letvak,(unknown)	5

About Laurie Letvak

Laurie Letvak is a scholar working on Hematology, Genetics and Rheumatology, having authored 31 papers that have together received 981 indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (24 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Acute Lymphoblastic Leukemia research (13 papers). The work is most often cited by research in Hematology (749 citations), Genetics (566 citations) and Rheumatology (514 citations). Laurie Letvak has collaborated with scholars based in United States, Switzerland and Germany. Frequent co-authors include Jörge E. Cortes, Hagop M. Kantarjian, Mary Beth Rios, Stefan Faderl, Francis J. Giles, Guillermo Garcia‐Manero, Moshe Talpaz, Alessandra Ferrajoli, Deborah A. Thomas and Susan O’Brien. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact